Rosiglitazone

also known as Avandia · rosiglitazone maleate · RSG · BRL49653C · RSG XR · rosiglitazone (Avandia) · Rosiglitazone Malate · Rosiglitazone XR · +4 more

Small molecule targets PPARG via activation

Developed for: type 2 diabetes mellitus · Alzheimer disease · metabolic syndrome X · glucose intolerance · HIV infectious disease · diabetes mellitus · atherosclerosis · lipodystrophy
+55 more
· metabolic dysfunction-associated steatohepatitis · obesity disorder · asthma · cardiovascular disorder · chronic kidney disease · coronary artery disorder · endometriosis · fatty liver disease · malaria · ulcerative colitis · ACTH-dependent Cushing syndrome · bipolar disorder · central nervous system neoplasm · chronic hepatitis C virus infection · cognitive impairment with or without cerebellar ataxia · congestive heart failure · critical illness polyneuropathy · depressive disorder · diabetic neuropathy · dilated cardiomyopathy · esophageal adenocarcinoma · female breast carcinoma · gastric adenocarcinoma · head and neck cancer · head and neck squamous cell carcinoma · hepatocellular carcinoma · hyperinsulinism · hyperlipidemia · hypertensive disorder · hypertriglyceridemia · intermediate coronary syndrome · ischemic disease · kidney disorder · melanoma · mycosis fungoides · NAFLD1 · non-small cell lung carcinoma · oral mucosa leukoplakia · pituitary tumor · Plasmodium falciparum malaria · polycystic ovary syndrome · prediabetes syndrome · rheumatoid arthritis · sarcoma · Sezary syndrome · type 1 diabetes mellitus · urinary bladder cancer · urothelial carcinoma · vascular disorder · diabetic kidney disease · focal segmental glomerulosclerosis · glucose metabolism disease · hepatitis C virus infection · latent autoimmune diabetes in adults · prostate adenocarcinoma
Investigated by: GlaxoSmithKline · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Baskent University · National Cancer Institute (NCI) · National Center for Research Resources (NCRR) · Novo Nordisk A/S
+105 more
· Aristotle University Of Thessaloniki · Canadian Institutes of Health Research (CIHR) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Gerstein, Hertzel, MD · James Lewis · Jonsson Comprehensive Cancer Center · Leiden University Medical Center · National Institutes of Health (NIH) · National Taiwan University Hospital · Radboud University Medical Center · Stanford University · US Department of Veterans Affairs · University of Glasgow · Abbott · Abbott RDx Cardiometabolic · Ahmad Slim · Amsterdam UMC, location VUmc · Association pour la Recherche sur les Maladies Hépatiques Virales · AstraZeneca · Aventis Pharmaceuticals · Barcelona Institute for Global Health · Bayer · Berlex Foundation · Beth Israel Medical Center · British Heart Foundation · Brooke Army Medical Center · CORDA, The Heart Charity · Cetero Research, San Antonio · Charite University, Berlin, Germany · Creighton University · Dan Zandberg · Dana-Farber Cancer Institute · Denver Research Institute · Dr. Milan Gupta · Eli Lilly and Company · Exelixis · Foundation Research, Florida · Fox Chase Cancer Center · Genentech, Inc. · Hadassah Medical Organization · Heart and Stroke Foundation of Ontario · Herlev Hospital · Hospital Authority, Hong Kong · Intermountain Health Care, Inc. · J JESUS VENEGAS, MD · Jean-Patrice Baillargeon · King Pharmaceuticals is now a wholly owned subsidiary of Pfizer · Korea University Anam Hospital · Kos Pharmaceuticals · Kyntra Bio · Laval University · M.D. Anderson Cancer Center · Mahidol University · Manhiça Health Research Centre · Mario Negri Institute for Pharmacological Research · McLaughlin-Rotman Center for Global Health, University of Toronto · Medstar Health Research Institute · Mexican Social Security Institute · Ministry of Health, Malaysia · Mutual Pharmaceutical Company, Inc. · National Cheng-Kung University Hospital · National Council of Science and Technology, Mexico · National Eye Institute (NEI) · National Health and Medical Research Council, Australia · National Heart, Lung, and Blood Institute (NHLBI) · National Institute of Allergy and Infectious Diseases (NIAID) · National Institute on Aging (NIA) · National Institutes of Health Clinical Center (CC) · National Science and Technology Council, Taiwan · Odense University Hospital · Pfizer · Royal Brompton & Harefield NHS Foundation Trust · Sanofi · Seoul St. Mary's Hospital · all 111 on the full record

Regulatory milestones approvals, filings & regulatory actions · 9 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Withdrawn	EU (EMA)	Avandia	—	2015-07-11	europa.eu ↗
Label expansions (6)	US (FDA)	AVANDIA	—	2000-04-03 – 2008-07-10	fda.gov ↗
Approved	EU (EMA)	Avandia	—	2000-07-11	europa.eu ↗
Approved	US (FDA)	AVANDIA	—	1999-05-25	fda.gov ↗

Trials 140 · started per year

today

US approved 1999

EU approved 2000

199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 120 trials
Phase 1	NCT01287598	Aug 2011 → Jul 2018	neoplasm	Bayer	Completed	No outcome recorded
Phase 1	NCT01402076	Aug 2011	—	Vanda Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT01209143	Nov 2010 → Mar 2012	—	Genentech, Inc.	Completed	No outcome recorded
Phase 1	NCT01100619	Apr 2010 → Aug 2012	renal cell carcinoma, thyroid Hurthle cell carcinoma, thyroid gland papillary carcinoma	Exelixis	Completed	No outcome recorded
Phase 1	NCT01376063	Mar → May 2010	—	Kyntra Bio	Completed	No outcome recorded
Phase 1	NCT01088594	Feb → Mar 2010	type 2 diabetes mellitus	Solvay Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT00964106	Aug 2009 → Aug 2011	—	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT00933309	Jul 2009 → Aug 2012	female breast carcinoma	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 1	NCT00884533	Jun → Aug 2009	Alzheimer disease	GlaxoSmithKline	Withdrawn	No outcome recorded
Phase 1	NCT00811356	Dec 2008 → Mar 2009	malaria	GlaxoSmithKline	Terminated	No outcome recorded
Phase 1	NCT00785213	Sep → Oct 2008	—	Mutual Pharmaceutical Company, Inc.	Completed	No outcome recorded
Phase 1	NCT00733785	Aug → Nov 2008	Alzheimer disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT00688207	Apr → Sep 2008	Alzheimer disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT00615212	Jan → Feb 2008	type 2 diabetes mellitus	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT00551564	Jul 2007 → Sep 2008	type 2 diabetes mellitus	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT00511823	Jul → Sep 2007	chemotherapy-induced toxicity	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT00443170	Nov 2006 → ?	anemia	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT00318630	Jul 2005 → Jun 2006	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT00039663	May 2002 → Oct 2005	HIV infectious disease	National Institutes of Health Clinical Center (CC)	Completed	No outcome recorded
Phase 1	NCT00006185	Sep 1999 → Aug 2003	HIV infectious disease, lipodystrophy	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	No outcome recorded

Phase 1/23 trials
Phase 1/2	NCT00309660	Nov 2005 → Jun 2007	ulcerative colitis	Herlev Hospital	Unknown	No outcome recorded
Phase 1/2	NCT00130286	Mar 2005 → Aug 2010	HIV infectious disease, lipodystrophy, metabolic syndrome X	Weill Medical College of Cornell University	Completed	No outcome recorded
Phase 1/2	NCT00149383	Dec 2004 → Nov 2005	Plasmodium falciparum malaria	Mahidol University	Completed	No outcome recorded
Phase 225 trials
Phase 2	NCT04114136	Sep 2020 → Apr 2032 expected	esophageal adenocarcinoma, gastric adenocarcinoma, head and neck squamous cell carcinoma, hepatocellular carcinoma +3	Dan Zandberg	Recruiting	No outcome recorded
Phase 2	NCT00614874	Dec 2008 → Feb 2010	asthma	Creighton University	Completed	No outcome recorded
Phase 2	NCT00699036	Apr 2007 → Jul 2009	NAFLD1, metabolic dysfunction-associated steatohepatitis	Brooke Army Medical Center	Unknown	No outcome recorded
Phase 2	NCT00405015	Apr 2007 → Jul 2008	abdominal obesity-metabolic syndrome, ischemic disease	Radboud University Medical Center	Completed	No outcome recorded
Phase 2	NCT00612066	Apr 2007 → Nov 2010	ACTH-dependent Cushing syndrome	Jonsson Comprehensive Cancer Center	Terminated	No outcome recorded
Phase 2	NCT01150981	Nov 2006 → Apr 2010	metabolic syndrome X	University of Massachusetts, Worcester	Completed	No outcome recorded
Phase 2	NCT00616642	Oct 2006 → Nov 2010	central nervous system neoplasm	Jonsson Comprehensive Cancer Center	Terminated	No outcome recorded
Phase 2	NCT00381238	Jun 2006 → Feb 2009	Alzheimer disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00242593	Jun 2006 → Dec 2011	cognitive impairment with or without cerebellar ataxia	University of Washington	Unknown	No outcome recorded
Phase 2	NCT00369174	Jun 2006 → Aug 2007	oral mucosa leukoplakia	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00115661	Jul 2005 → May 2006	endometriosis	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Terminated	No outcome recorded
Phase 2	NCT00178841	Jun 2005 → Mar 2007	Sezary syndrome, mycosis fungoides	Vanderbilt University	Completed	No outcome recorded
Phase 2	NCT00309309	Apr 2005 → Jul 2007	—	Mario Negri Institute for Pharmacological Research	Completed	No outcome recorded
Phase 2	NCT00334568	Dec 2004 → Jul 2007	Alzheimer disease	GlaxoSmithKline	Terminated	No outcome recorded
Phase 2	NCT00379600	Nov 2004 → Dec 2006	rheumatoid arthritis	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00098852	Oct 2004 → Jun 2010	head and neck cancer	University of California, San Francisco	Unknown	No outcome recorded
Phase 2	NCT00265148	May 2004 → Jul 2008	Alzheimer disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00370305	May 2004 → Oct 2008	glucose intolerance, metabolic syndrome X	Charite University, Berlin, Germany	Completed	No outcome recorded
Phase 2	NCT00064727	Jul 2003 → Apr 2007	congestive heart failure	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded
Phase 2	NCT00492700	Jan 2003 → ?	metabolic dysfunction-associated steatohepatitis	Association pour la Recherche sur les Maladies Hépatiques Virales	Completed	No outcome recorded
Phase 2	NCT00065065	Sep 2002 → Jan 2008	ulcerative colitis	James Lewis	Completed	No outcome recorded
Phase 2	NCT00018382	Oct 1999 → Mar 2003	Alzheimer disease	US Department of Veterans Affairs	Completed	No outcome recorded
Phase 2	NCT00004180	Oct 1999 → Mar 2006	sarcoma	Dana-Farber Cancer Institute	Completed	No outcome recorded
Phase 2	NCT00006493	—	HIV infectious disease, hyperlipidemia	National Center for Research Resources (NCRR)	Completed	No outcome recorded
Phase 2	NCT00015626	—	diabetes mellitus	National Center for Research Resources (NCRR)	Completed	No outcome recorded

Phase 2/33 trials
Phase 2/3	NCT00169923	Apr 2007 → May 2009	chronic kidney disease	Leiden University Medical Center	Withdrawn	No outcome recorded
Phase 2/3	NCT00121953	Jul 2005 → May 2008	endometriosis	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Withdrawn	No outcome recorded
Phase 2/3	NCT04148183	Jan 2004 → Jan 2005	—	J JESUS VENEGAS, MD	Completed	No outcome recorded
Phase 335 trials
Phase 3	NCT01453049	Apr → Oct 2010	type 2 diabetes mellitus	GlaxoSmithKline	Terminated	No outcome recorded
Phase 3	NCT00550420	Oct 2007 → Feb 2009	Alzheimer disease	GlaxoSmithKline	Terminated	No outcome recorded
Phase 3	NCT00490568	Aug 2007 → Jun 2009	Alzheimer disease	GlaxoSmithKline	Terminated	No outcome recorded
Phase 3	NCT00452166	Apr 2007 → Mar 2008	chronic kidney disease	Leiden University Medical Center	Terminated	No outcome recorded
Phase 3	NCT00428090	Feb 2007 → Sep 2008	Alzheimer disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00399711	Nov 2006 → Nov 2007	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 3	NCT01574820	Nov 2006 → Aug 2010	coronary artery disorder, glucose intolerance, prediabetes syndrome	National Cheng-Kung University Hospital	Completed	No outcome recorded
Phase 3	NCT00348140	Jul 2006 → Mar 2009	Alzheimer disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00432679	May 2006 → Mar 2007	type 2 diabetes mellitus	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00318422	May 2006 → May 2007	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 3	NCT00409097	Apr 2006 → Dec 2007	critical illness polyneuropathy, multiple organ dysfunction syndrome	Amsterdam UMC, location VUmc	Unknown	No outcome recorded
Phase 3	NCT00297063	Jan 2006 → May 2007	type 2 diabetes mellitus	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00465296	Jan 2006 → Jul 2007	metabolic syndrome X	Medstar Health Research Institute	Terminated	No outcome recorded
Phase 3	NCT00523913	Nov 2005 → Apr 2007	type 2 diabetes mellitus	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00349427	Oct 2005 → ?	type 2 diabetes mellitus	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00135330	Oct 2005 → Jul 2008	type 2 diabetes mellitus	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00240604	Apr 2005 → Dec 2013	glucose intolerance	Hadassah Medical Organization	Unknown	No outcome recorded
Phase 3	NCT00116831	Jan 2005 → Aug 2008	atherosclerosis	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00081328	May 2004 → Feb 2011	type 2 diabetes mellitus	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	No outcome recorded
Phase 3	NCT00359112	Feb 2004 → ?	type 2 diabetes mellitus	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00422955	Nov 2003 → Oct 2005	diabetic neuropathy	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00499707	Oct 2003 → Dec 2004	type 2 diabetes mellitus	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00203632	Sep 2003 → Oct 2007	diabetes mellitus	University of Calgary	Terminated	No outcome recorded
Phase 3	NCT00169832	Jun 2003 → Jul 2007	diabetes mellitus	Laval University	Completed	No outcome recorded
Phase 3	NCT00197132	Oct 2002 → Aug 2003	—	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00123227	Oct 2002 → May 2005	hypertensive disorder, type 2 diabetes mellitus	Royal Brompton & Harefield NHS Foundation Trust	Unknown	No outcome recorded
Phase 3	NCT00489229	Oct 2002 → Dec 2005	diabetes mellitus, glucose intolerance	Universiti Sains Malaysia	Completed	No outcome recorded
Phase 3	NCT00231387	Sep 2002 → May 2005	type 2 diabetes mellitus	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00140647	Jul 2001 → Jul 2006	atherosclerosis, glucose intolerance	Gerstein, Hertzel, MD	Completed	No outcome recorded
Phase 3	NCT00095654	Jul 2001 → Oct 2006	cardiovascular disorder, glucose intolerance	Gerstein, Hertzel, MD	Completed	No outcome recorded
Phase 3	NCT00379769	Apr 2001 → Dec 2008	type 2 diabetes mellitus	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00032487	Dec 2000 → May 2008	type 2 diabetes mellitus	VA Office of Research and Development	Completed	No outcome recorded
Phase 3	NCT00500955	Apr 2000 → Jun 2004	type 2 diabetes mellitus	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00279045	Jan 2000 → Jun 2006	type 2 diabetes mellitus	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01706211	Oct 1998 → Apr 2000	type 2 diabetes mellitus	National Taiwan University Hospital	Completed	No outcome recorded

Phase 431 trials
Phase 4	NCT00819910	Sep 2008 → May 2010	hypertriglyceridemia	Ahmad Slim	Terminated	No outcome recorded
Phase 4	NCT00567593	Oct 2007 → Mar 2008	inflammatory bowel disease	James Lewis	Completed	No outcome recorded
Phase 4	NCT00343395	Jun 2006 → Nov 2007	coronary artery disorder	Intermountain Health Care, Inc.	Terminated	No outcome recorded
Phase 4	NCT00314561	May → Dec 2006	metabolic syndrome X	Korea University Anam Hospital	Completed	No outcome recorded
Phase 4	NCT00225355	Feb → Nov 2006	metabolic syndrome X	University of Glasgow	Terminated	No outcome recorded
Phase 4	NCT00274495	Jan 2006 → Oct 2007	chronic hepatitis C virus infection, fatty liver disease	Beth Israel Medical Center	Terminated	No outcome recorded
Phase 4	NCT00300911	Dec 2005 → ?	type 2 diabetes mellitus	Baskent University	Completed	No outcome recorded
Phase 4	NCT00318656	Nov 2005 → Oct 2007	type 2 diabetes mellitus	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00440375	Jun 2005 → Mar 2006	obesity disorder, type 2 diabetes mellitus	Baskent University	Completed	No outcome recorded
Phase 4	NCT00424762	Feb 2005 → Apr 2007	type 2 diabetes mellitus	University of Texas Southwestern Medical Center	Completed	No outcome recorded
Phase 4	NCT00306176	Jan 2005 → Oct 2006	type 2 diabetes mellitus	Aristotle University Of Thessaloniki	Completed	No outcome recorded
Phase 4	NCT00364221	Nov 2004 → Jul 2006	metabolic syndrome X	University of Colorado, Denver	Completed	No outcome recorded
Phase 4	NCT00367055	Oct 2004 → Oct 2008	type 2 diabetes mellitus	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00571506	May 2004 → Aug 2007	type 2 diabetes mellitus, vascular disorder	University of Arkansas	Completed	No outcome recorded
Phase 4	NCT00290394	Mar → Aug 2004	type 2 diabetes mellitus	Baskent University	Completed	No outcome recorded
Phase 4	NCT00733174	Mar 2004 → Jan 2009	glucose intolerance	Denver Research Institute	Unknown	No outcome recorded
Phase 4	NCT01406704	Jan 2004 → Dec 2010	metabolic dysfunction-associated steatohepatitis	Seoul St. Mary's Hospital	Terminated	No outcome recorded
Phase 4	NCT00675740	Jan 2004 → Feb 2007	glucose intolerance	University of Leipzig	Completed	No outcome recorded
Phase 4	NCT00372086	Aug 2003 → Sep 2005	type 1 diabetes mellitus	The University of New South Wales	Completed	No outcome recorded
Phase 4	NCT00123643	May 2003 → Dec 2005	type 2 diabetes mellitus	St. Paul Heart Clinic	Completed	No outcome recorded
Phase 4	NCT00121966	Jan 2003 → Jul 2007	type 2 diabetes mellitus	Odense University Hospital	Completed	No outcome recorded
Phase 4	NCT00306696	Oct 2002 → Jan 2004	diabetes mellitus	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00329225	Sep 2002 → Apr 2004	type 2 diabetes mellitus	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00044460	May 2002 → Apr 2003	type 2 diabetes mellitus	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00306644	May 2002 → Nov 2004	type 2 diabetes mellitus	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00501020	Jun 2001 → Feb 2003	type 2 diabetes mellitus	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00358124	Jan 2001 → Jun 2002	type 2 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 4	NCT00304993	Jan 2001 → Feb 2005	metabolic syndrome X	Foundation Research, Florida	Completed	No outcome recorded
Phase 4	NCT00333723	Jul 2000 → Jan 2003	type 2 diabetes mellitus	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00225342	—	intermediate coronary syndrome, type 2 diabetes mellitus	University of Glasgow	Withdrawn	No outcome recorded
Phase 4	NCT00522470	—	obesity disorder, type 2 diabetes mellitus	Baskent University	Completed	No outcome recorded

Phase not applicable23 trials
—	NCT03309319	Oct 2016 → Dec 2018	pituitary tumor	Zhaoyun Zhang	Unknown	No outcome recorded
—	NCT02694874	Feb 2016 → Mar 2020	malaria	Manhiça Health Research Centre	Completed	No outcome recorded
—	NCT00242619	Jul 2007 → Dec 2009	bipolar disorder, depressive disorder	Stanford University	Completed	No outcome recorded
—	NCT00466713	Mar → Dec 2007	dilated cardiomyopathy	Stanford University	Terminated	No outcome recorded
—	NCT01019356	Aug 2006 → Jul 2021	polycystic ovary syndrome	Jean-Patrice Baillargeon	Completed	No outcome recorded
—	NCT00348309	Jul 2006 → Jan 2009	Alzheimer disease	GlaxoSmithKline	Completed	No outcome recorded
—	NCT00486187	Apr 2006 → Jun 2009	type 2 diabetes mellitus	Dr. Milan Gupta	Completed	No outcome recorded
—	NCT00516880	Mar 2006 → Nov 2008	cardiovascular disorder, kidney disorder	Hospital Authority, Hong Kong	Unknown	No outcome recorded
—	NCT00285805	Feb → Oct 2006	—	Radboud University Medical Center	Completed	No outcome recorded
—	NCT00282945	Jan 2006 → Oct 2007	type 2 diabetes mellitus	Pfizer	Terminated	No outcome recorded
—	NCT00252499	Oct 2005 → Aug 2010	fatty liver disease	US Department of Veterans Affairs	Terminated	No outcome recorded
—	NCT00154011	Sep 2005 → Jun 2006	—	Technical University Dresden	Completed	No outcome recorded
—	NCT00636766	Sep 2005 → Dec 2007	atherosclerosis, metabolic syndrome X, stroke disorder, type 2 diabetes mellitus	Aristotle University Of Thessaloniki	Completed	No outcome recorded
—	NCT00264251	Jul 2005 → Aug 2007	HIV infectious disease, obesity disorder	St. Luke's-Roosevelt Hospital Center	Completed	No outcome recorded
—	NCT00166803	Jun 2005 → Nov 2008	diabetes mellitus	National Taiwan University Hospital	Suspended	No outcome recorded
—	NCT00285142	Jun → Nov 2004	—	University Hospital, Montpellier	Completed	No outcome recorded
—	NCT00084578	Mar 2004 → Apr 2006	urinary bladder cancer	Fox Chase Cancer Center	Withdrawn	No outcome recorded
—	NCT00577590	Oct 2003 → Aug 2012	type 2 diabetes mellitus	Washington University School of Medicine	Completed	No outcome recorded
—	NCT00143624	Jun 2003 → Dec 2009	HIV infectious disease, atherosclerosis	University of British Columbia	Completed	No outcome recorded
—	NCT00549874	Feb 2002 → Nov 2006	type 2 diabetes mellitus	University of Michigan	Completed	No outcome recorded
—	NCT00025753	—	HIV infectious disease	National Center for Research Resources (NCRR)	Completed	No outcome recorded
—	NCT00015691	? → Jan 2006	HIV infectious disease, hyperinsulinism, lipodystrophy	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00483392	—	—	University Medical Centre Ljubljana	Completed	No outcome recorded

Also used as a comparator or background therapy in 53 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 16 trials
Phase 1	NCT01415128 Comparator	Apr → May 2010	erectile dysfunction	VIVUS LLC	Completed	No outcome recorded
Phase 1	NCT01872780 Comparator	Aug 2008 → Feb 2009	—	Inje University	Completed	No outcome recorded
Phase 1	NCT00607945 Background	Jan 2008 → May 2012	type 2 diabetes mellitus	Ohio State University	Completed	No outcome recorded
Phase 1	NCT00692510 Background	Nov 2007 → Sep 2008	Alzheimer disease	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT00362726 Comparator	Sep → Nov 2006	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 1	NCT00193648 Comparator	Jul 2005 → Oct 2007	focal segmental glomerulosclerosis	Northwell Health	Completed	No outcome recorded

Phase 26 trials
Phase 2	NCT00618072 Comparator	Jan 2008 → Jan 2011	hyperinsulinism, obesity disorder	New York Medical College	Completed	No outcome recorded
Phase 2	NCT00609362 Comparator	Jan 2008 → Nov 2009	osteoporosis	University of Aarhus	Completed	No outcome recorded
Phase 2	NCT00367744 Comparator	Jul 2006 → Dec 2008	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT01577095 Comparator	Apr 2006 → May 2007	type 2 diabetes mellitus	China Medical University Hospital	Completed	No outcome recorded
Phase 2	NCT00110851 Background	Apr 2005 → Aug 2007	type 2 diabetes mellitus	Wellstat Therapeutics	Completed	No outcome recorded
Phase 2	NCT00481663 Background	Aug 2003 → Jul 2004	type 2 diabetes mellitus	Merck Sharp & Dohme LLC	Completed	No outcome recorded

Phase 2/32 trials
Phase 2/3	NCT00831129 Comparator	Sep 2006 → Mar 2011	prediabetes syndrome	University of Chicago	Completed	No outcome recorded
Phase 2/3	NCT00119496 Comparator	Jul 2005 → Jun 2007	asthma	University of Glasgow	Completed	No outcome recorded
Phase 319 trials
Phase 3	NCT00975286 Background	Oct 2009 → Aug 2011	type 2 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 3	NCT00680745 Background	Apr 2008 → Nov 2009	type 2 diabetes mellitus	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00484419 Comparator	May 2007 → Apr 2008	hyperlipidemia, type 2 diabetes mellitus	Daiichi Sankyo	Completed	No outcome recorded
Phase 3	NCT00427154 Comparator	Jan 2007 → Mar 2008	type 2 diabetes mellitus	Novo Nordisk A/S	Terminated	No outcome recorded
Phase 3	NCT00348712 Comparator	Oct 2006 → Mar 2008	type 2 diabetes mellitus	Novo Nordisk A/S	Terminated	No outcome recorded
Phase 3	NCT00343980 Comparator	Oct 2006 → Mar 2008	type 2 diabetes mellitus	Novo Nordisk A/S	Terminated	No outcome recorded
Phase 3	NCT00396227 Comparator	Oct 2006 → Oct 2007	type 2 diabetes mellitus	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00350779 Background	Jun 2006 → Sep 2007	type 2 diabetes mellitus	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT00361868 Comparator	Jun 2006 → Dec 2007	glucose metabolism disease, hyperlipidemia	Solvay Pharmaceuticals	Terminated	No outcome recorded
Phase 3	NCT00541775 Comparator	Jun 2006 → Mar 2007	type 2 diabetes mellitus	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT00333151 Background	May 2006 → Aug 2007	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 3	NCT00295633 Background	Mar 2006 → Oct 2007	type 2 diabetes mellitus	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00131664 Comparator	Sep 2005 → Jan 2008	type 2 diabetes mellitus	Canadian Heart Research Centre	Completed	No outcome recorded
Phase 3	NCT00116922 Comparator	Jun 2004 → Jan 2010	diabetes mellitus, glucose intolerance	Samuel Lunenfeld Research Institute, Mount Sinai Hospital	Completed	No outcome recorded
Phase 3	NCT00324350 Comparator	Oct 2003 → Jun 2009	atherosclerosis, coronary artery disorder, hyperlipoproteinemia, hypertensive disorder +1	University of California, San Francisco	Completed	No outcome recorded
Phase 3	NCT00182052 Comparator	Sep 2000 → Aug 2003	prostate adenocarcinoma	Massachusetts General Hospital	Completed	No outcome recorded
Phase 3	NCT00331487 Comparator	Sep 2000 → Mar 2004	type 2 diabetes mellitus	Takeda	Completed	No outcome recorded
Phase 3	NCT00006305 Comparator	Sep 2000 → Nov 2008	coronary artery disorder, type 2 diabetes mellitus	University of Pittsburgh	Completed	No outcome recorded
Phase 3	NCT00000620 Background	Sep 1999 → Jun 2009	atherosclerosis, coronary artery disorder, hyperlipoproteinemia, hypertensive disorder +1	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded

Phase 414 trials
Phase 4	NCT06449235 Comparator	Sep 2024 → Apr 2025 overdue	type 2 diabetes mellitus	Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders	Not yet recruiting	No outcome recorded
Phase 4	NCT00879970 Comparator	May 2009 → Nov 2010	type 2 diabetes mellitus	GlaxoSmithKline	Terminated	No outcome recorded
Phase 4	NCT00948324 Comparator	Jun 2008 → May 2019	type 2 diabetes mellitus	Sun Yat-sen University	Suspended	No outcome recorded
Phase 4	NCT00679939 Comparator	Apr 2008 → Sep 2010	type 2 diabetes mellitus	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00953498 Comparator	Oct 2007 → Mar 2012	type 2 diabetes mellitus	Centre Hospitalier Universitaire Dijon	Completed	No outcome recorded
Phase 4	NCT00386100 Comparator	Oct 2006 → Sep 2009	type 2 diabetes mellitus	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00207402 Comparator	Oct 2005 → Jan 2010	hepatitis C virus infection	Brooke Army Medical Center	Completed	No outcome recorded
Phase 4	NCT00640224 Comparator	Mar 2005 → Jul 2015	polycystic ovary syndrome	Silva Arslanian	Completed	No outcome recorded
Phase 4	NCT00373178 Comparator	Jan 2005 → Jan 2007	type 2 diabetes mellitus	Aristotle University Of Thessaloniki	Completed	No outcome recorded
Phase 4	NCT00738023 Comparator	Mar 2004 → Dec 2009	hypertensive disorder, type 2 diabetes mellitus	Emory University	Completed	No outcome recorded
Phase 4	NCT00746174 Comparator	Feb 2004 → Mar 2007	—	University of Texas Southwestern Medical Center	Completed	No outcome recorded
Phase 4	NCT01045590 Comparator	Dec 2003 → Feb 2006	type 2 diabetes mellitus	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00337350 Comparator	Sep 2003 → Jan 2011	schizophrenia	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT02526615 Comparator	Oct 2000 → Dec 2001	type 2 diabetes mellitus	Turku University Hospital	Completed	No outcome recorded

Phase not applicable6 trials
—	NCT00776607 Comparator	Apr 2007 → Apr 2011	latent autoimmune diabetes in adults	Abertawe Bro Morgannwg University NHS Trust	Unknown	No outcome recorded
—	NCT00324675 Comparator	Aug 2006 → Dec 2008	diabetic kidney disease, type 2 diabetes mellitus	Technical University Dresden	Completed	No outcome recorded
—	NCT00413335 Comparator	Nov 2005 → Sep 2008	glucose intolerance, obesity disorder, type 2 diabetes mellitus	Yale University	Completed	No outcome recorded
—	NCT00186537 Comparator	Sep 2003 → Sep 2008	hypertriglyceridemia	Stanford University	Completed	No outcome recorded
—	NCT00225225 Comparator	Oct 2002 → Sep 2005	type 2 diabetes mellitus	Stanford University	Terminated	No outcome recorded
—	NCT00194896 Comparator	Feb 2000 → Sep 2008	type 2 diabetes mellitus	University of Washington	Completed	No outcome recorded

Press releases naming this drug 2 releases

Date	Issuer	Release
2007-09-27	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Settlement Of Generic Avandia®, Avandamet®, And Avandaryl® Litigation With Glaxosmithkline tevapharm.com ↗
2004-12-21	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Tentative Approval Of Rosiglitazone Maleate Tablets tevapharm.com ↗

Evidence & citations 17 cited values

Every value below carries the sentence it was read from. 197 sources stand behind the page.

Field	Value	Cited text
Known as	rosiglitazone	“An extended release (XR) formulation of rosiglitazone maleate (RSG), a new formulation of rosiglitazone, is being investigated as a treatment for patients with mild to moderate...” NCT00884533 ↗ 188 “Patients in the glibenclamide + rosiglitazone treatment group who have FPG \< 270mg/dL after the glibenclamide 5mg om run-in will receive glibenclamide 5mg om + rosiglitazone 4mg om.” NCT01045590 ↗ “Rosiglitazone improves glycemic control for patients with type 2 diabetes mellitus, but there remains controversy regarding an observed association with cardiovascular hazard.” PMID 23857320 ↗ Jul 2013 “This study compares the effects of Avandamet (rosiglitazone maleate/metformin) treatment and metformin plus sulphonylurea treatment in overweight people with type 2 diabetes.” NCT00359112 ↗ “combined rosiglitazone/metformin (Avandametä) to placebo in subjects with normal or intermediate fasting glucose (IFG) and stable coronary artery disease.” NCT00343395 ↗ “Patients will progress from lifestyle modification to metformin, to metformin with Rosiglitazone and finally insulin depending on HbA1c levels.” NCT00776607 ↗ “Rosiglitazone Versus Rosiglitazone and Metformin Versus Rosiglitazone and Avandia in the Treatment of Nonalcoholic Steatohepatitis (NASH)” NCT00699036 ↗ “Avandamet contains two drugs commonly used to control blood sugar levels in patients with diabetes (metformin and rosiglitazone).” NCT00933309 ↗ “Chemical Name: Thiazolidinediones (e.g., Pioglitazone, Rosiglitazone) Class: Thiazolidinediones (TZDs)” NCT06449235 ↗ “TZD (either rosiglitazone or pioglitazone) if given, to be continued at stable dose up to Week 24.” NCT00975286 ↗ “pioglitazone 30 mg (or rosiglitazone in countries where pioglitazone was not licensed)” NCT00481663 ↗ “Rosiglitazone was used by 74% and pioglitazone by 13% of participants.” PMID 26305617 ↗ Aug 2015 “RSG:CSII combined with three months rosiglitazoneor 4mg QD.” NCT00948324 ↗ “Avandamet (Rosiglitazone maleate/metformin hydrochloride)” NCT00386100 ↗ “Actos (pioglitazone), Avandia (rosiglitazone)” NCT00396227 ↗ “Rosiglitazone maleate on days 1 and 9” NCT01376063 ↗ “Rosiglitazone 8 mg single dose” NCT01577095 ↗ “Avandia (rosiglitazone)” NCT00207402 ↗ “rosiglitazone (Avandia)” NCT00000620 ↗ NCT00274495 ↗ NCT00616642 ↗ NCT00300911 ↗ NCT00348309 ↗ NCT00154011 ↗ NCT00492700 ↗ NCT00348140 ↗ NCT00166803 ↗ NCT00015691 ↗ NCT00032487 ↗ NCT00399711 ↗ NCT01406704 ↗ NCT01100619 ↗ NCT00265148 ↗ NCT00098852 ↗ NCT00193648 ↗ NCT00225355 ↗ NCT00331487 ↗ NCT00225342 ↗ NCT00465296 ↗ NCT00373178 ↗ NCT00337350 ↗ NCT00549874 ↗ NCT00953498 ↗ NCT00225225 ↗ NCT00361868 ↗ NCT00123227 ↗ NCT00428090 ↗ NCT00349427 ↗ NCT00499707 ↗ NCT00015626 ↗ NCT00522470 ↗ NCT00240604 ↗ NCT04148183 ↗ NCT00116831 ↗ NCT00169923 ↗ NCT00483392 ↗ NCT00169832 ↗ NCT01150981 ↗ NCT00290394 ↗ NCT00733785 ↗ NCT00424762 ↗ NCT00369174 ↗ NCT00362726 ↗ NCT00231387 ↗ NCT00333151 ↗ NCT00811356 ↗ NCT01088594 ↗ NCT00618072 ↗ NCT02526615 ↗ NCT00831129 ↗ NCT00295633 ↗ NCT00309660 ↗ NCT00367055 ↗ NCT00372086 ↗ NCT01574820 ↗ NCT00297063 ↗ NCT00379769 ↗ NCT00819910 ↗ NCT00609362 ↗ NCT00081328 ↗ NCT00879970 ↗ NCT00309309 ↗ NCT01872780 ↗ NCT00285142 ↗ NCT00746174 ↗ NCT00084578 ↗ NCT00203632 ↗ NCT00334568 ↗ NCT00550420 ↗ NCT00409097 ↗ NCT00785213 ↗ NCT00370305 ↗ NCT00452166 ↗ NCT00523913 ↗ NCT00135330 ↗ NCT00039663 ↗ NCT01019356 ↗ NCT00282945 ↗ NCT00615212 ↗ NCT00679939 ↗ NCT00304993 ↗ NCT00367744 ↗ NCT00064727 ↗ NCT00065065 ↗ NCT00733174 ↗ NCT00511823 ↗ NCT00490568 ↗ NCT00541775 ↗ NCT03309319 ↗ NCT00364221 ↗ NCT02694874 ↗ NCT00252499 ↗ NCT00551564 ↗ NCT00432679 ↗ NCT00306176 ↗ NCT00119496 ↗ NCT00692510 ↗ NCT00571506 ↗ NCT00577590 ↗ NCT00006493 ↗ NCT00285805 ↗ NCT00484419 ↗ NCT00264251 ↗ NCT00567593 ↗ NCT00680745 ↗ NCT00466713 ↗ NCT00413335 ↗ NCT00318422 ↗ NCT00640224 ↗ NCT00516880 ↗ NCT00121966 ↗ NCT00306644 ↗ NCT00614874 ↗ NCT00675740 ↗ NCT01287598 ↗ NCT00964106 ↗ NCT00123643 ↗ NCT00607945 ↗ NCT00318656 ↗ NCT00443170 ↗ NCT00004180 ↗ NCT00427154 ↗ NCT00329225 ↗ NCT00116922 ↗ NCT00140647 ↗ NCT00143624 ↗ NCT01453049 ↗ NCT00194896 ↗ NCT00738023 ↗ NCT00149383 ↗ NCT00350779 ↗ NCT00025753 ↗ NCT00186537 ↗ NCT00440375 ↗ NCT00358124 ↗ NCT01402076 ↗ NCT00314561 ↗ NCT00405015 ↗ NCT00110851 ↗ NCT04114136 ↗ NCT00688207 ↗ NCT00121953 ↗ NCT00242619 ↗ NCT00115661 ↗ NCT01209143 ↗ NCT00612066 ↗ NCT00242593 ↗ NCT00044460 ↗ NCT00018382 ↗ NCT00381238 ↗ NCT00348712 ↗ NCT00318630 ↗ NCT00324675 ↗ NCT00130286 ↗ NCT00182052 ↗ NCT00333723 ↗ NCT01415128 ↗ NCT00178841 ↗ NCT00501020 ↗ NCT00279045 ↗ NCT00306696 ↗ NCT00343980 ↗ NCT00636766 ↗ NCT00500955 ↗ NCT00486187 ↗ NCT00379600 ↗ NCT00095654 ↗ NCT00422955 ↗ NCT00489229 ↗
Known as	Avandia	“Effect of Rosiglitazone Maleate (Avandia®) on Carotid Intima Media Thickness, Brachial Artery Reactivity, Glucose Metabolism, Blood Lipid Concentrations, Body Fat Distribution,...” NCT00143624 ↗ 12 “This study was designed to evaluate the safety and efficacy of AVANDIA (rosiglitazone) (8mg once daily) in African American and Hispanic patients with type 2 diabetes mellitus.” NCT00333723 ↗ “This study utilizes the drug rosiglitazone (Avandia)to treat the effects of airway inflammation in patients with asthma.” NCT00614874 ↗ “Rosiglitazone (also called "Avandia") is used to treat insulin resistance in people who have diabetes” NCT00130286 ↗ “AvandiaTM and AmarylTM combine two antidiabetic agents, rosiglitazone maleate and glimepiride.” NCT00131664 ↗ “receive either placebo (control) or rosiglitazone, Avandia®, 4 mg daily for 2 weeks.” NCT00121953 ↗ “Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer” NCT00182052 ↗ “Rosiglitazone (Avandia®): PPARgamma agonist IND69,782:” NCT00193648 ↗ “Avandia® (Rosiglitazone Maleate)” NCT00484419 ↗ “rosiglitazone (Avandia)” NCT00025753 ↗ “Avandia (Rosiglitazone)” NCT00064727 ↗ NCT00006185 ↗ NCT00197132 ↗
Known as	Avandia (GlaxoSmithKline)	“Avandia (GlaxoSmithKline)” NCT00675740 ↗
Known as	Avandia (rosiglitazone)	“Avandia (rosiglitazone)” NCT00207402 ↗
Known as	BRL-049653	“A Study to Evaluate the Efficacy of Rosiglitazone (BRL-049653) on Reduction of Microalbuminuria in Subjects With Type 2 Diabetes Mellitus” NCT00500955 ↗
Known as	BRL49653C	“Clinical Evaluation of Rosiglitazone Malate (BRL49653C) in Patients With Type 2 Diabetes Mellitus -Long-term Study of Rosiglitazone Maleate-” NCT00523913 ↗ 3 “Clinical Evaluation of Rosiglitazone Malate (BRL49653C) in Patients With Type 2 Diabetes Mellitus” NCT00297063 ↗ “Rosiglitazone (BRL49653C)” NCT00432679 ↗ NCT01706211 ↗
Known as	rosiglitazone (Avandia)	“rosiglitazone (Avandia)” NCT00000620 ↗ 1 “rosiglitazone: AVANDIA” NCT00953498 ↗
Known as	Rosiglitazone Malate	“Clinical Evaluation of Rosiglitazone Malate (BRL49653C) in Patients With Type 2 Diabetes Mellitus -Long-term Study of Rosiglitazone Maleate-” NCT00523913 ↗ 1 “Clinical Evaluation of Rosiglitazone Malate (BRL49653C) in Patients With Type 2 Diabetes Mellitus” NCT00297063 ↗
Known as	rosiglitazone maleate	“Effect of Rosiglitazone Maleate (Avandia®) on Carotid Intima Media Thickness, Brachial Artery Reactivity, Glucose Metabolism, Blood Lipid Concentrations, Body Fat Distribution,...” NCT00143624 ↗ 8 “An extended release (XR) formulation of rosiglitazone maleate (RSG), a new formulation of rosiglitazone, is being investigated as a treatment for patients with mild to moderate...” NCT00884533 ↗ “Clinical Evaluation of Rosiglitazone Malate (BRL49653C) in Patients With Type 2 Diabetes Mellitus -Long-term Study of Rosiglitazone Maleate-” NCT00523913 ↗ “Patients receive 4 mg oral rosiglitazone maleate once daily in week 1 and then 8 mg once daily beginning in week 2” NCT00616642 ↗ “Participants in this arm receive 4 mg of study drug (rosiglitazone maleate) twice daily by mouth.” NCT00004180 ↗ “Drug: rosiglitazone maleate” NCT00551564 ↗ “Drug: rosiglitazone maleate” NCT00484419 ↗ “Drug: rosiglitazone maleate” NCT00369174 ↗ “rosiglitazone maleate” NCT00084578 ↗
Known as	Rosiglitazone XR	“Rosiglitazone XR (extended release) oral tablets” NCT00334568 ↗ 1 “Drug: Rosiglitazone XR” NCT00490568 ↗
Known as	RSG	“This was a randomized, double-blind, double dummy, multicenter study to assess the safety, efficacy and tolerability of the addition of RSG (rosiglitazone) to sub-maximal MET...” NCT00501020 ↗ 7 “Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable...” NCT00348309 ↗ “An extended release (XR) formulation of rosiglitazone maleate (RSG), a new formulation of rosiglitazone, is being investigated as a treatment for patients with mild to moderate...” NCT00884533 ↗ “Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable...” NCT00348140 ↗ “After a 1-year randomized trial, 53 patients underwent a control liver biopsy and were enrolled in an open-label extension trial of rosiglitazone (RSG), 8 mg/day for 2 additional years.” PMID 19877169 ↗ Feb 2010 “Subjects were randomized to rosiglitazone (RSG) or metformin (MET) for 52 wk followed by 24 wk of open-label MET.” PMID 27052635 ↗ Mar 2016 “The efficacy of diuretics in the management of rosiglitazone (RSG)-induced fluid retention was evaluated” PMID 17093067 ↗ Nov 2006 “either rosiglitazone (RSG) 4 mg b.i.d or matching placebo (PLC) for 52 weeks” PMID 22723267 ↗ Jun 2012
Known as	RSG XR	“All subjects will receive rosiglitazone extended-release (RSG XR) 4mg once daily for the first 4 weeks of the study followed by 8mg RSG XR as adjunctive therapy to their...” NCT00490568 ↗ 2 “All subjects will receive rosiglitazone extended-release (RSG XR) 4mg once daily for the first 4 weeks of the study followed by 8mg RSG XR.” NCT00550420 ↗ “Extended Release Formulation of Rosiglitazone (RSG XR)” NCT00688207 ↗
Known as	TZD	“rosiglitazone (TZD) and electroacupuncture (EA) combined therapy” NCT01577095 ↗
Action	Activate	“Rosiglitazone, a Full-Agonist Ligand for the Peroxisome Proliferator-Activated Receptor Gamma (PPAR)” NCT00004180 ↗
Modality	Small molecule	“insulin-sensitizing compounds” NCT00018382 ↗
Route	Oral	“Patients receive oral rosiglitazone twice daily.” NCT00004180 ↗
Target	PPARG	“Rosiglitazone works by stimulating the PPAR gamma system.” NCT00006493 ↗